Always administer at different inj sites if to be given at the same time as another injectable vaccine. Closely observe for at least 15 min following vaccination in case of anaphylactic event. Postpone vaccination in individuals suffering from acute severe febrile illness. Do not administer intravascularly or intradermally. Caution in individuals w/ thrombocytopenia or any coagulation disorder following IM administration. Patients receiving immunosuppressive treatment or those w/ immunodeficiency may have reduced immune response to Arexvy. Minor influence on ability to drive & use machines. Not recommended during pregnancy & in breast-feeding/lactating women. Safety & efficacy in childn have not been established.